Connexion
E-mail
Mot de passe
Afficher le mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON

Les Barons de la Bourse

Toute l'infoNos articlesSociétésMarchésEconomie & ForexMat. PremièresTauxBarons de la boursePro. de la financeAgendaSecteurs 
AccueilToute l'actualitéLes news les plus luesBiographies des Barons
Synthèse 
Martin W. MacKay is an American businessperson who founded Rallybio Corp. and Rallybio LLC and who has been at the head of 8 different companies. Currently, Dr. MacKay is Chairman & Chief Executive Officer of Rallybio Corp., Chairman & Chief Executive Officer at Rallybio LLC and Chief Executive Officer & Director at Rallybio Holdings LLC (both are subsidiaries of Rallybio Corp.), Chief Executive Officer of Calyx Group Ltd. (Ireland) and Senior Advisor at New Leaf Venture Partners LLC.

He is also on the board of Charles River Laboratories International, Inc., Charles River Laboratories, Inc., Novo Nordisk An and 5:01 Acquisition Corp.

In the past Martin W. MacKay occupied the position of Chief Executive Officer & Director at Neverfail, Inc. and Chief Executive Officer & Director at Neverfail Group Ltd. (a subsidiary of Neverfail, Inc.), Senior Vice President-Worldwide Development at Pfizer Inc. and President at Pfizer (St. Louis) (a subsidiary of Pfizer Inc.), President-Research & Development at AstraZeneca Plc and Global Head-Research & Development at Alexion Pharmaceuticals, Inc. (a subsidiary of AstraZeneca Plc), Vice President-International at VeriSign, Inc., Principal at PeopleSoft USA, Inc., Principal at Beecham Pharmaceuticals (UK), Chief Executive Officer at Vecta Software Corp. Ltd., Operations Director at The Dun & Bradstreet Corp., Head-Drug Preformulation & Delivery at BASF Performance Products Ltd. (United Kingdom), Head-Molecular & Cell Biology at CRI Worldwide LLC, Principal at Accenture LLC, Director-Business Development at NorthgateArinso, Inc. and Head-Drug Preformulation & Delivery at Ciba-Geigy Pharmaceuticals.

Martin W. MacKay received an undergraduate degree from Heriot-Watt University and a doctorate from The University of Edinburgh.


Postes et responsabilités de Martin W. MacKay 
Nom Titre Depuis
Novo Nordisk A/S
(Produits pharmaceutiques)
Independent Director 2018
Charles River Laboratories International, Inc.
(Recherche biotechnologique et médicale)
Independent Director 2017
Rallybio Corporation
(Recherche biotechnologique et médicale)
Chairman & Chief Executive Officer 2018
5:01 Acquisition Corp.
(Sociétés holdings)
Independent Director 2020
Calyx Group Ltd. (Ireland) Chief Executive Officer -
Rallybio LLC Chairman & Chief Executive Officer 2018
Charles River Laboratories, Inc. Independent Director -
Rallybio Holdings LLC Chief Executive Officer & Director -
New Leaf Venture Partners LLC Senior Advisor 2018


Participations de Martin W. MacKay 
Nom Actions%Valorisation
Rallybio Corporation (RLYB)
(Recherche biotechnologique et médicale)
709 1262,21%12 657 899 USD
Charles River Laboratories International, Inc. (CRL)
(Recherche biotechnologique et médicale)
9 5990,019%4 306 879 USD
5:01 Acquisition Corp.30 0001,30%294 900 USD


Martin W. MacKay: Réseau personnel 
Actualités les plus lues 
01/12CARLOS TAVARES : Le coût de l'électrification pour la filière auto "dépasse les limites", dit Tavares
RE
24/11ELON MUSK : Musk vend des actions Tesla d'une valeur de 1,05 milliard de dollars et achète 2,15 millions d'actions.
ZR
24/11BERNARD TAPIE : L'avenir de Stéphane Richard chez Orange suspendu à une décision de justice
RE
03/12ELON MUSK : les cessions d’actions se poursuivent pour Elon Musk
AO
30/11JACK DORSEY : Jack Dorsey poursuit son rêve de crypto et fintech sur Twitter
ZR
20/11VINCENT BOLLORÉ : Le groupe Dassault dément vouloir céder Le Figaro
RE
24/11JAMIE DIMON : Jamie Dimon plaisante en disant que JPMorgan survivra au parti communiste chinois.
ZR
29/11FRANÇOIS VILLEROY DE GALHAU : Omicron ne devrait pas modifier significativement les prévisions économiques, dit Villeroy de Galhau
RE
22/11ELON MUSK : USA-Les valeurs à suivre à Wall Street (actualisé)
RE
29/11JACK DORSEY : cotation suspendue dans l'attente d'un communiqué
CF
Plus d'actualités


© 2021 People and Ownership :   
Martin W. MacKay : Connexions